Daniel Dolan - 28 Jan 2022 Form 4 Insider Report for Nabriva Therapeutics plc

Role
Chief Financial Officer
Signature
/s/ J. Christopher Naftzger, by power of attorney
Issuer symbol
N/A
Transactions as of
28 Jan 2022
Net transactions value
$0
Form type
4
Filing time
01 Feb 2022, 17:39:01 UTC
Next filing
15 Aug 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NBRV Share Options Award $0 +83,200 $0.000000 83,200 28 Jan 2022 Ordinary Shares 83,200 $0.4500 Direct F1, F2
transaction NBRV Restricted Stock Units Award $0 +41,600 $0.000000 41,600 28 Jan 2022 Ordinary Shares 41,600 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option was granted on January 28, 2022, subject to shareholder approval; provided, that if such shareholder approval is not obtained, the option will remain outstanding and convert into a cash-settled share appreciation right.
F2 Subject to the reporting person's continued employment with Nabriva Therapeutics plc (the "Issuer"), the option will vest over a four-year period beginning January 28, 2023. Twenty-five percent (25%) of the option will vest on the one (1) year anniversary of the date of grant, and the remaining seventy-five percent (75%) of the option will vest on a monthly pro-rata basis over the remaining vesting period.
F3 The restricted stock units ("RSU") were granted on January 28, 2022, and each RSU represents a contingent right to receive one ordinary share of the Issuer subject to shareholder approval; provided, that if such shareholder approval is not obtained, then each RSU will represent the right to receive the economic equivalent of one ordinary share of the Issuer in cash on the applicable vesting date.
F4 Subject to the reporting person's continued employment with the Issuer, the RSUs will vest in equal annual installments over four years with the first installment vesting on January 28, 2023.